Cargando…

Chaperone-Dependent Mechanisms as a Pharmacological Target for Neuroprotection

Modern pharmacotherapy of neurodegenerative diseases is predominantly symptomatic and does not allow vicious circles causing disease development to break. Protein misfolding is considered the most important pathogenetic factor of neurodegenerative diseases. Physiological mechanisms related to the fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voronin, Mikhail V., Abramova, Elena V., Verbovaya, Ekaterina R., Vakhitova, Yulia V., Seredenin, Sergei B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820882/ https://www.ncbi.nlm.nih.gov/pubmed/36614266 http://dx.doi.org/10.3390/ijms24010823

Ejemplares similares

Chaperone Sigma1R and Antidepressant Effect
por: Voronin, Mikhail V., et al.
Publicado: (2020)

Neuroprotective Properties of Quinone Reductase 2 Inhibitor M-11, a 2-Mercaptobenzimidazole Derivative
por: Voronin, Mikhail V., et al.
Publicado: (2021)

Pharmacological Analysis of GABA(A) Receptor and Sigma1R Chaperone Interaction: Research Report I―Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABA(A) Receptors’ Ligands
por: Voronin, Mikhail V., et al.
Publicado: (2023)

Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole
por: Voronin, Mikhail V., et al.
Publicado: (2021)

Deferred Administration of Afobazole Induces Sigma1R-Dependent Restoration of Striatal Dopamine Content in a Mouse Model of Parkinson’s Disease
por: Kadnikov, Ilya A., et al.
Publicado: (2020)

Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson’s disease
por: Voronin, Mikhail V., et al.
Publicado: (2019)

Analysis of Antidepressant-like Effects and Action Mechanisms of GSB-106, a Small Molecule, Affecting the TrkB Signaling
por: Vakhitova, Yulia V., et al.
Publicado: (2021)

Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
por: Ostrovskaya, Rita U, et al.
Publicado: (2014)

Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept
por: Vakhitova, Y. V., et al.
Publicado: (2016)

Dimeric mimetic of BDNF loop 4 promotes survival of serum-deprived cell through TrkB-dependent apoptosis suppression
por: Zainullina, L. F., et al.
Publicado: (2021)

Galactosemia: Towards Pharmacological Chaperones
por: Banford, Samantha, et al.
Publicado: (2021)

Chaperone-Mediated Autophagy in Neurodegenerative Diseases: Molecular Mechanisms and Pharmacological Opportunities
por: Wang, Yi-Ting, et al.
Publicado: (2022)

On the Neuroprotective Effects of Naringenin: Pharmacological Targets, Signaling Pathways, Molecular Mechanisms, and Clinical Perspective
por: Nouri, Zeinab, et al.
Publicado: (2019)

Pharmacological chaperone therapy for Fabry disease
por: ISHII, Satoshi
Publicado: (2012)

Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses
por: Losada Díaz, Juan Camilo, et al.
Publicado: (2019)

Pharmacological Chaperone Therapy for Pompe Disease
por: Borie-Guichot, Marc, et al.
Publicado: (2021)

The neuroprotective potential of endoplasmic reticulum chaperones
por: McLaughlin, Todd, et al.
Publicado: (2015)

Molecular and pharmacological chaperones for SOD1
por: Wright, Gareth S.A.
Publicado: (2020)

Second-Generation Pharmacological Chaperones: Beyond Inhibitors
por: Tran, My Lan, et al.
Publicado: (2020)

Dealing with Misfolded Proteins: Examining the Neuroprotective Role of Molecular Chaperones in Neurodegeneration
por: Ali, Yousuf O., et al.
Publicado: (2010)

Tornado type closed magnetic trap for an ECR source
por: Abramova, K B, et al.
Publicado: (1999)

Neuroprotection by Endoplasmic Reticulum Stress-Induced HRD1 and Chaperones: Possible Therapeutic Targets for Alzheimer’s and Parkinson’s Disease
por: Nomura, Jun, et al.
Publicado: (2016)

Possible Neuroprotective Mechanisms of Physical Exercise in Neurodegeneration
por: Mahalakshmi, B., et al.
Publicado: (2020)

Co-Chaperones in Targeting and Delivery of Misfolded Proteins to the 26S Proteasome
por: Abildgaard, Amanda B., et al.
Publicado: (2020)

4-Hexylresorcinol: pharmacologic chaperone and its application for wound healing
por: Kim, Seong-Gon
Publicado: (2022)

Targeting inflammasome-dependent mechanisms as an emerging pharmacological approach for osteoarthritis therapy
por: Ramirez-Perez, Sergio, et al.
Publicado: (2022)

Targeted stabilization of Munc18‐1 function via pharmacological chaperones
por: Abramov, Debra, et al.
Publicado: (2020)

Chaperone Hsp70 (HSPA1) Is Involved in the Molecular Mechanisms of Sleep Cycle Integration
por: Simonova, Valentina V., et al.
Publicado: (2022)

Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson’s Disease
por: Kopytova, Alena E., et al.
Publicado: (2023)

Phenylalanine Hydroxylase Misfolding and Pharmacological Chaperones
por: Underhaug, Jarl, et al.
Publicado: (2012)

Pharmacological Chaperones and Protein Conformational Diseases: Approaches of Computational Structural Biology
por: Grasso, Daniela, et al.
Publicado: (2023)

Chaperoning Proteins for Destruction: Diverse Roles of Hsp70 Chaperones and their Co-Chaperones in Targeting Misfolded Proteins to the Proteasome
por: Shiber, Ayala, et al.
Publicado: (2014)

Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
por: Voronin, Denis V., et al.
Publicado: (2021)

Amburana cearensis: Pharmacological and Neuroprotective Effects of Its Compounds
por: Silva, Juliana Helena Castro e, et al.
Publicado: (2020)

Neuroprotective and neuroregenerative potential of pharmacologically-induced hypothermia with D-alanine D-leucine enkephalin in brain injury
por: Liska, M. Grant, et al.
Publicado: (2018)

Pharmacological targeting of host chaperones protects from pertussis toxin in vitro and in vivo
por: Ernst, Katharina, et al.
Publicado: (2021)

Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations
por: Liguori, Ludovica, et al.
Publicado: (2020)

Design and synthesis of biologically active carbaglycosylamines: From glycosidase inhibitors to pharmacological chaperones
por: OGAWA, Seiichiro, et al.
Publicado: (2022)

Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase
por: Bendikov-Bar, Inna, et al.
Publicado: (2013)

Azasugar inhibitors as pharmacological chaperones for Krabbe disease
por: Hill, Chris H., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cvkqh8keu8j0s9enh6496o34t2